Sign in

Jason M. Schenkel

@jmschenkel.bsky.social
510 followers 439 following 22 posts

T cell immunologist. Transfusion med doc. Assistant Professor in Lab Medicine, Immunology, and TMP @mdanderson.bsky.social

PostsRepliesMedia
Jason M. Schenkel @jmschenkel.bsky.social · 08/05/2026
Frog immunology! This is frog-tastic.
020
Reposted by Jason M. Schenkel
The Journal of Immunology @jimmunol.bsky.social · 08/05/2026
According to new data, frog mast cells are distinct from neutrophils and share many features associated with mammalian mast cells, such as degranulation and the release of immune proteins and lipid mediators. Read these evolutionary insights in The JI: ow.ly/eccV50YNBbO.
Xenopus laevis bone marrow and peritoneal precursor cells cultured with rSCF exhibit characteristic mast cell morphology and express a mast cell-specific protease. Mast cell cultures were generated from bone marrow (BMMCs) or peritoneal (PMCs) precursors and treated with rSCF. Neutrophils were derived from bone marrow precursors and treated with recombinant granulocyte colony-stimulating factor (rGCSF). (A) Giemsa staining of PMCs and BMMCs shows canonical mast cell morphology, distinct from cultured neutrophils, which have multilobed nuclei. (B) PMCs and BMMCs express the mast cell-specific CPA3, which was not detected in neutrophils. CPA3 messenger RNA was visualized by in situ hybridization using RNAscope. (C) PMCs and BMMCs contain intracellular heparin-positive granules, detected using Avidin-TxRed. Neutrophils lacked heparin staining. False coloring was applied to grayscale Giemsa cytology images (Fig. S1).
041
Jason M. Schenkel @jmschenkel.bsky.social · 03/04/2026
Are you interested in immunology and have a background in bioinformatics? Come work with my incredible collaborator, Dr. Kristen Pauken, at MD Anderson Cancer Center! See this linkedin post for more details or feel free to reach out! www.linkedin.com/feed/update/...
linkedin.com
Postdoctoral Fellow - Immunology at MD Anderson | Kristen Pauken
The Pauken Lab is hiring! In the open postdoctoral fellow position, the Pauken laboratory is specifically recruiting applicants with extensive computational expertise to drive single cell transcripto...
031
Jason M. Schenkel @jmschenkel.bsky.social · 20/01/2026
Thrilled to be honored as one of the 2026 Young Physician Scientist Awards from the @the-asci.org! Looking forward to being back in my old stomping grounds in Chicago!!! @mdanderson.bsky.social
161
Reposted by Jason M. Schenkel
Center for Immunology-UMN @cfi-umn.bsky.social · 25/08/2025
With deep gratitude, we thank Dr. Marc Jenkins for his decades of leadership, mentorship, and dedication to the Center for Immunology. The foundation he built will guide and inspire us for years to come.
2166
Jason M. Schenkel @jmschenkel.bsky.social · 24/07/2025
Fantastic new paper looking at the extrinsic effects of PD-1 loss! Check it out.
1121
Reposted by Jason M. Schenkel
UT MD Anderson Cancer Center @mdanderson.bsky.social · 11/07/2025
Congratulations to the 2025 Sabin Family Fellowship recipients, 10 early career researchers recognized for their bold, high-impact cancer research. Thank you to the Sabin Family Fellowship for supporting the next generation of innovators. spr.ly/633254IbgR #EndCancer
spr.ly
MD Anderson announces 10th cohort of Andrew Sabin Family Fellows
The University of Texas MD Anderson Cancer Center today announced its 10th cohort of Andrew Sabin Family Fellows, comprised of 10 early career cancer researchers. Created to provide a dedicated source of funding for emerging clinician and scientist leaders, the Sabin Family Fellowship supports groundbreaking research that fuels MD Anderson’s mission to end cancer.
052
Reposted by Jason M. Schenkel
Aria Vaishnavi, PhD @drariav.bsky.social · 09/05/2025
I am thrilled to share that the first preprint from my lab is now available on bioRxiV! In this study, our team elucidates the role of autocrine ligands in the aberrant behavior of oncogene-driven lung cancer. www.biorxiv.org/content/10.1...
biorxiv.org
BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling
Secretion of ligands of the human epidermal growth factor (EGFR) family of receptors or erythroblastic leukemia viral oncogene family (ERBB1-4) is a feature common to many cancer cells. However, our u...
1166
Reposted by Jason M. Schenkel
Center for Immunology-UMN @cfi-umn.bsky.social · 02/04/2025
Kicking off our journey on BlueSky! We're excited to share updates and connect with you. Follow us and help us get the word out! For more information about the Center for Immunology, go to our website: immunology.umn.edu
immunology.umn.edu
Center for Immunology
1198
Reposted by Jason M. Schenkel
Rachel Rutishauser @rrutishauser.bsky.social · 20/03/2025
Excited to share this preprint: In trial led by @michaelpelusomd.bsky.social and Steve Deeks, combination immunotherapy=>high rate of HIV control (low VL) after ART pause. @demisandel.bsky.social in our lab found control associated with robust CD8+ T cell proliferation early in response to rebound.
0125
Reposted by Jason M. Schenkel
Waggoner Lab @labwaggoner.bsky.social · 13/03/2025
Different injection routes and fluorophores affect anti-CD45.2 antibody leukocyte labeling @jmschenkel.bsky.social @jimmunol.bsky.social @thenatcat.bsky.social doi.org/10.1093/jimm...
051
Jason M. Schenkel @jmschenkel.bsky.social · 10/03/2025
I am pleased to announce that our newest story is officially out at @jimmunol.bsky.social ! academic.oup.com/jimmunol/adv... This is an immediate follow up to the lab’s first paper from last year. We again thank @jimmunol.bsky.social for a smooth, efficient, and wonderfully fair review process. 1/n
162
Reposted by Jason M. Schenkel
Wen Jiang MD, PhD @wenjiang-nano.bsky.social · 25/02/2025
Our newest article is online @naturecancer.bsky.social A new antibody drug conjugate that doesn’t kill tumor cells but rely on immune system to eradicate cancer. @bettykimmdphd.bsky.social @mdanderson.bsky.social
nature.com
An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy
Nature Cancer - Schrank et al. report the design and characterization of an antibody–toxin conjugate targeting CD47, promoting anti-tumor immunity in preclinical cancer models.
0102
Reposted by Jason M. Schenkel
Mark Kaplan @statfourwork.bsky.social · 24/01/2025
My last editorial in @ImmunoHorizons the little @immunologyaai.bsky.social journal that could. In this commentary I discuss some of the challenges facing academia. academic.oup.com/immunohorizo...
academic.oup.com
Give the grant-writing monkeys another banana
You’re probably familiar with the concept that if you had a million monkeys typing on a million computers for a million years, you would eventually get Sha
093
Reposted by Jason M. Schenkel
Vineet Joag @vjoag.bsky.social · 22/01/2025
Super excited to announce that the Joag Lab will officially open at @UW, @SCRI in March 2025! We will study the interplay between memory T cells and stromal, humoral, and innate immunity in mucosal tissues. researcherprofiles.seattlechildrens.org/Vineet.Joag. Hiring a technician and a postdoc!
Building Cure at the Seattle Children's Research Institute
2159
Jason M. Schenkel @jmschenkel.bsky.social · 22/12/2024
39 rotations around the sun! And what a year it's been. The lab has doubled in size. We had our first (3!!!) graduate students and post docs join the lab. We had both our first and second lab papers EVER accepted - the first is out in print... so check it out -(journals.aai.org/jimmunol/art...).
journals.aai.org
Longitudinal Intravascular Antibody Labeling Identified Regulatory T Cell Recruitment as a Therapeutic Target in a Mouse Model of Lung Cancer
Key Points. IV anti-CD45.2 label lasts for 3 days and tracks leukocyte migration to tissue.There is continuous innate and adaptive leukocyte migration in a
1122
Jason M. Schenkel @jmschenkel.bsky.social · 17/12/2024
Attention physician scientists! Are you interested in applying for a K08? Of course you are! I will be part of a NIH broadcasted information session featuring myself and another K08 awardee, as well as a reviewer from a K08 study section in January. See the attached flyer! And please repost!
153
Reposted by Jason M. Schenkel
Kat Mayer-Barber,PhD @mayerbarber.bsky.social · 06/12/2024
Best #Nikolaus 🎅! Our paper on how the 🫁 microenvironment can shape #innate immunity against #viruses is out @sciimmunology.bsky.social This was a herculean effort brilliantly led by @pauljbaker.bsky.social who singlehandedly established the model in the lab during the pandemic. 🧪 #Immunosky 1/9
Graphical summary of our paper.  In mice, prior lower airway exposure to diverse inflammatory stimuli, including chronic bacterial infections such as M. tuberculosis, acute bacterial infections such as pulmonary S. aureus, viral infections such as Influenza A, type-II allergic responses such as the OVA-Alum model, activation of pulmonary TLR9 by CpG or pulmonary TLR1/2 by Pam3CSK4
 leads to reduced viral burden upon subsequent infection with SARS-CoV-2 (SCV2). (2) This SCV2 restriction occurs prior to induction of SCV2-specific adaptive immune responses 
and is mediated through innate immune responses, including the induction of IFN-I, TNFα and IL-1 and sustained changes to the TRM (Tissue resident macrophage) cellular 
compartment and the pulmonary epithelium. (3) Innate cytokine and TLR signaling to both recruited immune cells and the pulmonary epithelium creates a microenvironment in the 
lung that limits early replication of SCV2. IFN-I signaling to pulmonary ECs (epithelial cells) increases expression of interferon-stimulated genes, that likely cell-intrinsically limit viral
 replication. TNF- or IL-1 suppress SCV2 independently of IFN-I signaling. TNF acts exclusively through radio-resistant cell types such as the lung epithelium, whereas IL-1 affords 
control both direct and indirectly, through either stromal and hematopoietic cell types, to restrict overall early SCV2 burden.
2829584
Reposted by Jason M. Schenkel
Padmanee (Pam) Sharma, MD, PhD @pamsharmamdphd.bsky.social · 25/11/2024
www.nature.com/articles/s41... Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
nature.com
Next-generation combination approaches for immune checkpoint therapy - Nature Immunology
In this Review, Sharma and colleagues describe the current landscape of combination therapies and discuss requirements for the development of effective combination strategies.
17827